Seeking Alpha

HowardCCC

HowardCCC
Send Message
View as an RSS Feed
Latest  |  Highest rated
  • Plavix: Winners and Losers [View article]
    Seems more likely that CYP2C19 testing will increase Plavix sales because the 25% of US patients who are CYP2C19 intermediate metabolizers will need double the dose. Only the 5% of patients who are poor metabolizers will need to be changed to another drug such as Effient. With Effient just coming to market and Plavix going off patent in 2011 it may be that payers will require a CYP2C19 test before paying for Effient.

    Howard Coleman
    Genelex Corp
    Jan 23 12:36 PM | Likes Like |Link to Comment
COMMENTS STATS
1 Comment
0 Likes